Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed EBITDA Margin for 16 consecutive years, with 10.79% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 704403.0% year-over-year to 10.79%, compared with a TTM value of 21.64% through Dec 2025, up 2578736.0%, and an annual FY2025 reading of 3.83%, up 1694895.0% over the prior year.
  • EBITDA Margin was 10.79% for Q4 2025 at Arrowhead Pharmaceuticals, up from 6.71% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 67.83% in Q1 2025 and bottomed at 7033.24% in Q4 2024.
  • Average EBITDA Margin over 5 years is 808.98%, with a median of 165.89% recorded in 2021.
  • The sharpest move saw EBITDA Margin tumbled -368990bps in 2023, then skyrocketed 704403bps in 2025.
  • Year by year, EBITDA Margin stood at 229.28% in 2021, then soared by 71bps to 67.04% in 2022, then tumbled by -5504bps to 3756.94% in 2023, then plummeted by -87bps to 7033.24% in 2024, then skyrocketed by 100bps to 10.79% in 2025.
  • Business Quant data shows EBITDA Margin for ARWR at 10.79% in Q4 2025, 6.71% in Q3 2025, and 639.91% in Q2 2025.